Evidence map›Paper›PMID 33846335›Full record

ArticleNature communications2021

Therapeutic B-cell depletion reverses progression of Alzheimer's disease.

Ki Kim, Xin Wang, Emeline Ragonnaud, Monica Bodogai, Tomer Illouz, Marisa DeLuca, Ross A McDevitt, Fedor Gusev, Eitan Okun, Evgeny Rogaev and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 197 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Ki Kim *Immunoregulation Section, Laboratory of Immunology and Molecular Biology, National Institute on Aging, Baltimore, MD, USA.ORCID 0000-0002-8028-0772
Xin Wang *Immunoregulation Section, Laboratory of Immunology and Molecular Biology, National Institute on Aging, Baltimore, MD, USA.
Emeline Ragonnaud *Immunoregulation Section, Laboratory of Immunology and Molecular Biology, National Institute on Aging, Baltimore, MD, USA.
Monica Bodogai *Immunoregulation Section, Laboratory of Immunology and Molecular Biology, National Institute on Aging, Baltimore, MD, USA.
Tomer IllouzThe Mina and Everard Goodman faculty of Life Sciences, Ramat Gan, Israel.ORCID 0000-0003-4123-6469
Marisa DeLucaImmunoregulation Section, Laboratory of Immunology and Molecular Biology, National Institute on Aging, Baltimore, MD, USA.ORCID 0000-0003-2057-6149
Ross A McDevittMouse Phenotyping Unit, Comparative Medicine Section, National Institute on Aging, Baltimore, MD, USA.
Fedor GusevDepartment of Genomics and Human Genetics, Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.
Eitan OkunThe Mina and Everard Goodman faculty of Life Sciences, Ramat Gan, Israel.ORCID 0000-0001-8474-1487
Evgeny RogaevDepartment of Genomics and Human Genetics, Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.
Arya BiragynImmunoregulation Section, Laboratory of Immunology and Molecular Biology, National Institute on Aging, Baltimore, MD, USA. biragyna@mail.nih.gov.ORCID 0000-0001-5276-6102
National Institute on Aging · USBar-Ilan University · ILUniversity of Massachusetts Chan Medical School · USVavilov Institute of General Genetics · RU

Funding

NIA IRP Comparative Medicine SectionZIGAG000621 · NIA · NATIONAL INSTITUTE ON AGING · PI WILGENBURG, BRIAN · 2009 to 2025
$139.6M
Epigenetic-Genetic Modulations in Aging and Alzheimer's Disease NeuronsR01AG054712 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROGAEV, EVGENY I · 2017 to 2021
$3.3M
The role of immune cells in Alzheimer's diseaseZIAAG000778 · NIA · NATIONAL INSTITUTE ON AGING · PI BIRAGYN, ARYA · 2017 to 2023
$3.1M
NIA NIH HHS R01 AG054712
6 · The paper itself

Abstract

The function of B cells in Alzheimer's disease (AD) is not fully understood. While immunoglobulins that target amyloid beta (Aβ) may interfere with plaque formation and hence progression of the disease, B cells may contribute beyond merely producing immunoglobulins. Here we show that AD is associated with accumulation of activated B cells in circulation, and with infiltration of B cells into the brain parenchyma, resulting in immunoglobulin deposits around Aβ plaques. Using three different murine transgenic models, we provide counterintuitive evidence that the AD progression requires B cells. Despite expression of the AD-fostering transgenes, the loss of B cells alone is sufficient to reduce Aβ plaque burden and disease-associated microglia. It reverses behavioral and memory deficits and restores TGFβ

Indexed as

Disease ProgressionLymphocyte DepletionAlzheimer DiseaseAmyloid beta-PeptidesAnimalsB-LymphocytesFemaleHippocampusHumansInterleukin-1betaLymphocyte ActivationMiceMice, Inbred C57BLMice, TransgenicMicrogliaPhenotypeAmyloid beta-PeptidesInterleukin-1betaTransforming Growth Factor beta

Identifiers

PMID33846335
PMCPMC8042032
OpenAlexW3153691873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.